One-Year, Efficacy and Safety Open Label Study, with a Single Injection of a New Hyaluronan for Knee OA: The SOYA Trial

Autor: Gavín C, Blanco FJ, Pablos JL, Caracuel MA, Rosas J, Gómez-Barrena E, Navarro F, Coronel MP, Gimeno M

Publikováno v: Journal of Pain Research, Vol Volume 14, Pp 2229-2237 (2021)

Carlos Gavín,1 Francisco J Blanco,2 José L Pablos,3 Miguel A Caracuel,4 José Rosas,5 Enrique Gómez-Barrena,6 Francisco Navarro,7 María Pilar Coronel,8 Mercedes Gimeno8 1Hospital Universitario Fundación Alcorcón, Madrid, Spain; 2Complejo Hospit

Externí odkaz: https://doaj.org/article/f53d9ca2a3584736bf4db05b8187072c

Patient Decision Aid (PDA) for Patients with Rheumatoid Arthritis Reduces Decisional Conflict and Improves Readiness for Treatment Decision Making

Autor: Pablos JL, Jover JA, Roman-Ivorra JA, Inciarte-Mundo J, Dilla T, Sacristan JA, Comellas M, Lizán L

Publikováno v: PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

The aim of this study was to develop and assess the effectiveness of a patient decision aid (PDA) to support treatment decision making in Spanish patients with moderate-to-severe rheumatoid arthritis (RA) who fail to achieve the therapeutic goal with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::f9f4ed353227ed9bf4fe9a8614da333d
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=11056

Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: the randomised JUST-ACT study

Autor: Pablos, JL, Navarro, F, Blanco, FJ, Roman-Ivorra, JA, Alonso, A, Mola, EM, Cantalejo, M, Ercole, L, Rivero, N

Publikováno v: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Objective The aim of the JUST-ACT study was to assess whether the add-on effect of tocilizumab (TCZ) to background methotrexate (MTX) observed in MTX-inadequate responders with active rheumatoid arthritis (RA), would be sustained when MTX is withdraw

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::736bd5a987ea8188094f3cc354281fce
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10758

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

Autor: Tak, Pp, Rigby, Wf, Rubbert Roth, A, Peterfy, Cg, van Vollenhoven RF, Stohl, W, Hessey, E, Chen, A, Tyrrell, H, Shaw, Tm, Aelion J, IMAGE I. n. v. e. s. t. i. g. a. t. o. r. s., Afif, N, Ahmadi, F, Aires, F, Alanis, E, Alonso, Cs, Alten, Rh, Alvaro Gracia JM, Ashrafzadeh, A, Ballina, J, Bambara, Lm, Bao, C, Bell, M, Berney, S, Bessette, L, Birbara, C, Boling, E, Bourgeois, P, Braun, J, Briones, H, Brzezicki, J, Burgos Vargos, R, Burmester, G, Burnett, M, Busch, H, Cabello, E, Calvo, A, Cantagrel, A, Cantini, F, Zea, Ac, Carreño Perez, L, Chavez, J, Shim, Sc, Chindalore, V, Chiriac, R, Codding, C, Danda, D, Del Guidice, J, De Vita, S, Digiovanni, R, Dikranian, A, Eider, W, Fantini, F, Ferraccioli, G, Fietchner, J, Filipowicz Sosnowska, A, Finnanger, B, Fiocco, G, Fleck, M, Fleischmann, R, Fraser, A, Gaudin, P, Gauler, G, Gaylis, N, Gerlag, Dm, Godde, J, Gomez Reino JJ, Gornisiewicz, M, Gough, W, Greenwald, M, Guerra, G, Hackshaw, K, Haentzschel, Hm, Hammond, T, Hazleman, Bl, Heilig, B, Herenius, Mm, Hilliquin, P, Holt, D, Huang, F, Huff, J, Huizinga, T, Isaacs, J, Jaffer, A, Amante, Ej, Jeka, S, Jimenez, R, Jones, G, Jones, R, Kaine, J, Kashif, A, Kaufmann, C, Kay, J, Khraishi, M, Kivitz, A, Klinkhoff, A, Kraag, G, Krystufkova, O, Kucharz, E, Lawson, J, Leirisalo Repo, M, Levin, R, Liang, G, Liang, P, Limonta, M, Lowenstein, M, Rodriguez Lozano, C, Lue, C, Mahowald, M, Maradiaga, M, Maricic, M, Mariette, X, Martin, L, Massarotti, E, Matucci Cerinic, M, Montecucco, Cm, Mazurov, V, Mcnally, J, Mehta, D, Meyer, O, Misra, R, Moreland, Lw, Mueller Ladner, U, Myerson, G, Nasonov, E, Navarra, S, Navarro, F, Neal, N, Olech, E, Olsen, N, Pablos, Jl, Pacheco, C, Pal, S, Palomo, Er, Pandith, V, Penserga, Eg, Prupas, H, Radominski, S, Ramos Remus, C, Reid, D, Riordan, K, Rosenberg, D, Ruiz, A, Saadeh, C, Salvarani, Carlo, Samuels, A, Sanmarti, R, Sarzi Puttini, P, Saxe, P, Schechtman, J, Scoville, C, Sedlackova, M, Sedrish, M, Sejer Hansen, M, Sibilia, J, Siebert, S, Specker, C, Stern, S, Szechinski, J, Tahir, H, Taylor, A, Thompson, Pw, Tony, Hp, Tornero, J, Trapp, R, Tremblay, Jl, Valesini, G, Van Den Bosch, F, Wanchu, A, Wassenberg, S, Ximenes, Ac, Kim, Hy, Zanetakis, E, Zazueta, B, Zerbini, C.

Publikováno v: Annals of the Rheumatic Diseases, 70(1), 39-46. BMJ Publishing Group
Annals of the rheumatic diseases, 70(1), 39-46. BMJ Publishing Group

Objectives: Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c80a94d92fa815c8602c1c10bf00fd4d
https://doi.org/10.1136/ard.2010.137703

Lack of Association with Rheumatoid Arthritis of Selected Polymorphisms in 4 Candidate Genes: CFH, CD209, Eotaxin-3, and MHC2TA

Autor: Dieguez-Gonzalez, R, Akar, S, Calaza, M, Gonzalez-Alvaro, I, Fernandez-Gutierrez, B, Lamas, JR, de la Serna, AR, Caliz, R, Blanco, FJ, Pascual-Salcedo, D, Velloso, ML, Perez-Pampin, E, Pablos, JL, Navarro, F, Narvaez, J, Lopez-Longo, FJ, Herrero-Beaumont, G, Gomez-Reino, JJ, Gonzalez, A

Publikováno v: JOURNAL OF RHEUMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

Objective. To investigate associations with rheumatoid arthritis (RA) of single-nucleotide polymorphisms (SNP) in 4 candidate genes, complement factor H (CFH), CD209 or DC-SIGN, eotaxin-3, and the MHC class II Transactivator (MHC2TA) genes. These SNP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::d2fb4a31f2a0630f8c3e13dc4c3d274b
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=13181